APRI对ALT&lt;2倍正常值上限慢性HBV感染抗病毒治疗指征的判断价值

陈晨; 翟玉峰; 张怀宏

doi:10.3969/j.issn.1001-5256.2018.05.016

APRI对ALT<2倍正常值上限慢性HBV感染抗病毒治疗指征的判断价值

DOI: 10.3969/j.issn.1001-5256.2018.05.016

1. 新乡医学院研究生学院
2. 郑州大学附属南阳市中心医院感染病科

详细信息

中图分类号: R512.62
计量
- 文章访问数: 301
- HTML全文浏览量: 14
- PDF下载量: 76
- 被引次数: 0
出版历程
- 收稿日期: 2017-10-23
- 出版日期: 2018-05-20

Value of aspartate aminotransferase-to-platelet ratio index in judging the indication for antiviral therapy in patients with chronic HBV infection and alanine aminotransferase less than two times of upper limit of normal

Xinxiang Medical College Graduate School

摘要

摘要:
目的评价AST与PLT比值指数（APRI）对ALT＜2倍正常值上限（ULN)慢性HBV感染者抗病毒治疗指征（肝脏炎症活动度分级≥G2或肝纤维化分期≥S2）的判断价值。方法回顾性分析2015年1月-2017年6月南阳市中心医院收治的ALT水平＜2×ULN慢性HBV感染者207例，根据炎症分级和纤维化分期分为＜G2和＜S2组（87例）与≥G2或≥S2组（120例）。记录其肝穿刺活组织检查结果和实验室检查结果，并计算APRI评分；利用Spearman相关分析判断APRI与炎症活动度分级和纤维化分期的相关性。采用受试者工作特征曲线下面积（AUC）比较ALT、AST、PLT及APRI对ALT＜2×ULN患者抗病毒适应证的判断效果。计量资料2组间比较采用t检验或Wilcoxon秩和检验；计数资料2组间比较采用χ2检验。结果APRI与炎症活动度分级及纤维化分期呈正相关（r值分别为0.661、0.597，P值均＜0.001）。在ALT、AST、PLT、APRI对抗病毒适应证的判断效果中，APRI的判断价值最高，其对判断≥G2或≥S2组、≥G2组、≥S2组的AUC分别为0.913、0.882、0.881。APRI 预测≥G2或≥S2组的AUC为 0913（95%可信区间为0.871~0.954），最佳截断值为0.5324；当APRI≥0.5324 时，患者存在显著的肝组织学病变，即肝组织炎症活动度分级≥G2或纤维化分期≥S2，达到抗病毒治疗的适应证；其预测的灵敏度、特异度、阳性预测值、阴性预测值分别为8750%、89.66%、92.11%、83.87%。结论APRI对于协助了解ALT＜2×ULN的慢性HBV感染者的肝脏病理变化、决定抗病毒治疗时机有较好的判断价值，可减少临床应用肝穿刺有创评估组织学改变的频率。
- 肝炎病毒,乙型 /
- APRI评分 /
- 丙氨酸转氨酶 /
- 治疗
Abstract:
Objective To investigate the value of aspartate aminotransferase-to-platelet ratio index ( APRI) in judging the indication for antiviral therapy [liver inflammation grade ( G) ≥2 or fibrosis stage ( S) ≥2] in patients with chronic HBV infection and alanine aminotransferase ( ALT) < 2 × upper limit of normal ( ULN) . Methods A retrospective analysis was performed for the clinical data of 207 patients with chronic HBV infection and ALT < 2 × ULN who were admitted to Nanyang Central Hospital from January 2015 to June 2017, and according to liver inflammation grade and fibrosis stage, these patients were divided into G < 2 + S < 2 group with 87 patients and G≥2 or S≥2 group with 120 patients. The results of liver biopsy and laboratory examination were recorded, and APRI was calculated. The Spearman correlation analysis was performed to investigate the correlation of APRI with liver inflammation grade and fibrosis stage. The area under the receiver operating characteristic curve ( AUC) was used to investigate the value of ALT, aspartate aminotransferase ( AST) , platelet count ( PLT) , and APRI in judging the indication for antiviral therapy in patients with ALT < 2 × ULN. The t-test or the Wilcoxon rank-sum test was used for comparison of continuous data between two groups, and the chi-square test was used for comparison of categorical data between two groups. Results APRI was positively correlated with liver inflammation grade and fibrosis stage ( r = 0. 661 and 0. 597, P<0. 001) . Among ALT, AST, PLT, and APRI, APRI had the highest value in judging the indication for antiviral therapy, with AUCs of0. 913 in the G≥2 or S≥2 group, 0. 882 in the G≥2 group, and 0. 881 in the S≥2 group. APRI had an AUC of 0. 913 ( 95% confidence interval: 0. 871-0. 954) in predicting the indication in the G≥2 or S≥2 group at the optimal cut-off value of 0. 5324; when APRI was ≥0. 5324, the patients had marked liver histological changes, i. e., G≥2 or S≥2, which met the indication for antiviral therapy. APRI had a sensitivity of 87. 50%, a specificity of 89. 66%, a positive predictive value of 92. 11%, and a negative predictive value of 83. 87%. Conclusion For patients with chronic HBV infection and ALT < 2 × ULN, APRI has a good value in evaluating liver pathological changes and judging the timing of antiviral therapy and can reduce the frequency of invasive assessment of histological changes via liver biopsy.
- hepatitis B virus /
- APRI score /
- alanine transaminase /
- therapy

HTML全文

参考文献(16)

[1]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention andtreatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.

[2]TERRAULT NA, BZOWEJ NH, CHANG KM, et al.AASLD guidelines for treatment of chronic hepatitis B[J].Hepatology, 2016, 63 (1) :261-283.

[3]SARIN SK, KUMAR M, LAU GK, et al.Asian-Pacific clinical practice guidelines on the mana-agement of hepatitis B:a 2015update[J].Hepatol Int, 2016, 10 (1) :1-98.

[4]JIANG SW, HU AR, YAN HD, et al.Analysis on the judgment values of three non-invasive score systems (LIF-5, APRI and FIB-4) for trement indication in chronic HBV infected patients with ALT less than two times of upper limits of normal[J].Chin J Gene Pract, 2017, 15 (4) :558-561. (in Chinese) 蒋素文, 胡爱荣, 颜华东, 等.诊断模型对ALT正常值上限2倍以下慢性HBV感染者治疗指征的判断价值[J].中华全科医学, 2017, 15 (4) :558-561.

[5]HU XQ.Is liver biopsy the gold standard for assessment of liver fibrosis?[J].Chin J Hepatol, 2012, 20 (8) :568-570. (in Chinese) 胡锡琪.肝穿刺活组织检查是评估肝纤维化的金标准吗?[J].中华肝脏病杂志, 2012, 20 (8) :568-570.

[6]PAN JJ, SUN QL.Clinical utility of aspartate aminotransferase to platelet ratio index in chronic hepatitis B virus infection with transaminase less than two times of upper limits of normal[J].Chin J Infect Dis, 2014, 32 (1) :48-51. (in Chinese) 潘劲劲, 孙秋林.天冬氨酸转移酶与血小板比值在转氨酶正常值上限两倍以下慢性乙型肝炎病毒感染者中的临床应用价值[J].中华传染病杂志, 2014, 32 (1) :48-51.

[7] LIU YR, ZENG DW, CUI SH, et al.Validation of a noninvasive diagnostic model for liver cirrhosis in patients with chronic hepatitis B[J].Chin J Clin Infect Dis, 2013, 31 (12) :719-723. (in Chinese) 刘豫瑞, 曾达武, 崔首华, 等.慢性乙型肝炎患者肝硬化无创诊断模型的验[J].中华传染病杂志, 2013, 31 (12) :719-723.

[8]LI X, ZHANG ZH, CAI Q, et al.Judgement of liver fibrosis by gama-glutamyltransferase to q HBs Ag ratio in patients with chronic hepatitis B[J].J Pract Hepatol, 2015, 18 (2) :141-144. (in Chinese) 李旭, 张振华, 蔡群, 等.谷氨酰转肽酶/HBs Ag比值评估慢性乙型肝炎患者肝纤维化的价值探讨[J].实用肝脏病杂志, 2015, 18 (2) :141-144.

[9]YANG Q, DING SB, YAN YC, et al.Ultrasound and blood indicators in diagnosis of early cirrhosis for patients with chronic hepatitis B[J].Chin J Clin Infect Dis, 2014, 7 (4) :339-345. (in Chinese) .杨晴, 丁世斌, 颜迎春, 等.血液及超声指标对慢性乙型肝炎早期肝硬化的诊断价值[J].中华临床感染病杂志, 2014, 7 (4) :339-345.

[10]HE XM, HUANG J.Recent advances in serum biomarkers for liver fibrosis[J].Chin J Hepatol, 2015, 23 (11) :874-877. (in Chinese) 何肖敏, 黄坚.肝纤维化血清学标志物研究新进展[J].中华肝脏病杂志, 2015, 23 (11) :874-877.

[11]HE XM, LI SW, LYU TX, et al.Study on the diagnostic significance of level of serum autoantibodies in fibrosis staging in patients with chronic HBV hepatitis[J].J Clin Exp Med, 2016, 15 (7) :632-636. (in Chinese) 何肖敏, 李斯文, 吕婷霞, 等.血清自身抗体在乙肝肝纤维化分期中的诊断价值研究[J].临床和实验医学杂志, 2016, 15 (7) :632-636.

[12]UCAR F, SEZER S, GINIS Z, et al.APRI, the FIB-4 score, and Forn’s indexhave noninvasive diagnostic value for liver fibrosis in patients with chronic hepatitis B[J].Eur J Gastroenterol Hepatol, 2013, 25 (9) :1076-1081.

[13]QIN JH, ZHANG GD, BAI LJ, et al.The diagnostic value of Fibroscan and APRI in liver fibrosis[J/CD].Chin J Liv Dis:Electronic Version, 2015, 7 (3) :106-108. (in Chinese) 秦金环, 张国栋, 白留江, 等.Fibroscan与谷草转氨酶-血小板指数 (APRI) 诊断肝纤维化的价值[J/CD].中国肝脏病杂志:电子版, 2015, 7 (3) :106-108.

[14]LI Q, REN X, LU C, et al.Evaluation of APRI and FIB-4 for noninvasive assessment of significant fibrosis and cirrhosis in HBe Ag-negative CHB patients with ALT<2×ULN[J].Medicine, 2017, 96 (12) :6336-6343.

[15]ZHU X, WANG LC, CHEN EQ, et al.Prospective evaluation of Fibro Scan for the diagnosis of hepatic fibrosis compared with liver biopsy/AST platele tratio index and FIB-4 inpatients with chronic HBV infection[J].Dig Dis Sci, 2011, 56 (9) :2742-2749.

[16]CHEN N, HUANG WE, SU MH, et al.Correlation between platelet indices and liver pathological staging:an analysis of 167 patients with chronic hepatitis B[J].J Clin Hepatol, 2016, 32 (1) :106-109. (in Chinese) 陈念, 黄卫娥, 苏明华, 等.慢性乙型肝炎患者血小板指数与肝组织病理的关系[J].临床肝胆病杂志, 2016, 32 (1) :106-109.

施引文献

资源附件(0)

访问统计